Advertisement

Amniotic fluid microRNA profiles in twin-twin transfusion syndrome with and without severe recipient cardiomyopathy

      Background

      Twin-twin transfusion syndrome presents many challenges for clinicians, and the optimal means of identifying pregnancies that will benefit most from intervention is controversial. There is currently no clinically available biomarker to detect twin-twin transfusion syndrome or to stratify cases based on the risk factors. microRNAs are small RNAs that regulate gene expression and are biomarkers for various disease processes, including adult and pediatric heart failure. To date, no studies have investigated amniotic fluid microRNAs as biomarkers for disease severity, specifically for severe recipient cardiomyopathy in twin-twin transfusion syndrome cases.

      Objective

      This study aimed to assess whether amniotic fluid microRNAs could be useful as biomarkers to identify pregnancies at greatest risk for severe recipient cardiomyopathy associated with twin-twin transfusion syndrome.

      Study Design

      Amniotic fluid was collected at the time of amnioreduction or selective fetoscopic laser photocoagulation from monochorionic diamniotic twin pregnancies with twin-twin transfusion syndrome at any stage. Fetal echocardiography was performed on all twins before the procedure, and severe cardiomyopathy was defined as a right ventricular myocardial performance index of the recipient fetus of >4 Z-scores. microRNA was extracted from the amniotic fluid samples and analyzed using an array panel assessing 379 microRNAs (TaqMan Open Array, ThermoFisher). Student t tests were performed to determine significant differences in microRNA expression between pregnancies with severe recipient cardiomyopathy and those with preserved cardiac function. A stringent q value of <.0025 was used to determine differential microRNA expression. Random forest plots identified the top 3 microRNAs that separated the 2 groups, and hierarchical cluster analysis was used to determine if these microRNAs properly segregated the samples according to their clinical groups.

      Results

      A total of 14 amniotic fluid samples from pregnancies with twin-twin transfusion syndrome with severe cardiomyopathy were compared with samples from 12 twin-twin transfusion syndrome control cases with preserved cardiac function. A total of 110 microRNAs were identified in the amniotic fluid samples. Twenty microRNAs were differentially expressed, and the top 3 differentiating microRNAs were hsa-miR-200c-3p, hsa-miR-17-5p, and hsa-miR-539-5p. Hierarchical cluster analysis based on these top 3 microRNAs showed a strong ability to differentiate severe cardiomyopathy cases from controls. The top 3 microRNAs were used to investigate the sensitivity and specificity of these microRNAs to differentiate between the 2 groups with a receiver operating characteristic curve demonstrating sensitivity and specificity of 80.8%. All 20 differentially expressed microRNAs were down-regulated in the group with severe cardiomyopathy.

      Conclusion

      Amniotic fluid microRNAs demonstrated differential expression between twin-twin transfusion syndrome recipient fetuses with severe cardiomyopathy and those without and have the potential to be important biomarkers of disease severity in this population.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Lewi L.
        • Jani J.
        • Blickstein I.
        • et al.
        The outcome of monochorionic diamniotic twin gestations in the era of invasive fetal therapy: a prospective cohort study.
        Am J Obstet Gynecol. 2008; 199: 514.e1-514.e8
        • Simpson L.L.
        • Society for Maternal-Fetal Medicine
        Twin-twin transfusion syndrome.
        Am J Obstet Gynecol. 2013; 208: 3-18
        • Behrendt N.
        • Galan H.L.
        Twin-twin transfusion and laser therapy.
        Curr Opin Obstet Gynecol. 2016; 28: 79-85
        • Quintero R.A.
        • Morales W.J.
        • Allen M.H.
        • Bornick P.W.
        • Johnson P.K.
        • Kruger M.
        Staging of twin-twin transfusion syndrome.
        J Perinatol. 1999; 19: 550-555
        • Habli M.
        • Michelfelder E.
        • Cnota J.
        • et al.
        Prevalence and progression of recipient-twin cardiomyopathy in early-stage twin-twin transfusion syndrome.
        Ultrasound Obstet Gynecol. 2012; 39: 63-68
        • Wohlmuth C.
        • Gardiner H.M.
        • Diehl W.
        • Hecher K.
        Fetal cardiovascular hemodynamics in twin-twin transfusion syndrome.
        Acta Obstet Gynecol Scand. 2016; 95: 664-671
        • Shah A.D.
        • Border W.L.
        • Crombleholme T.M.
        • Michelfelder E.C.
        Initial fetal cardiovascular profile score predicts recipient twin outcome in twin-twin transfusion syndrome.
        J Am Soc Echocardiogr. 2008; 21: 1105-1108
        • Barrea C.
        • Alkazaleh F.
        • Ryan G.
        • et al.
        Prenatal cardiovascular manifestations in the twin-to-twin transfusion syndrome recipients and the impact of therapeutic amnioreduction.
        Am J Obstet Gynecol. 2005; 192: 892-902
        • Michelfelder E.
        • Tan X.
        • Cnota J.
        • et al.
        Prevalence, spectrum, and outcome of right ventricular outflow tract abnormalities in twin-twin transfusion syndrome: a large, single-center experience.
        Congenit Heart Dis. 2015; 10: 209-218
        • Villa C.R.
        • Habli M.
        • Votava-Smith J.K.
        • et al.
        Assessment of fetal cardiomyopathy in early-stage twin-twin transfusion syndrome: comparison between commonly reported cardiovascular assessment scores.
        Ultrasound Obstet Gynecol. 2014; 43: 646-651
        • Fesslova V.
        • Villa L.
        • Nava S.
        • Mosca F.
        • Nicolini U.
        Fetal and neonatal echocardiographic findings in twin-twin transfusion syndrome.
        Am J Obstet Gynecol. 1998; 179: 1056-1062
        • Harkness U.F.
        • Crombleholme T.M.
        Twin-twin transfusion syndrome: where do we go from here?.
        Semin Perinatol. 2005; 29: 296-304
        • Rychik J.
        • Tian Z.
        • Bebbington M.
        • et al.
        The twin-twin transfusion syndrome: spectrum of cardiovascular abnormality and development of a cardiovascular score to assess severity of disease.
        Am J Obstet Gynecol. 2007; 197: 392.e1-392.e8
        • Stirnemann J.J.
        • Mougeot M.
        • Proulx F.
        • et al.
        Profiling fetal cardiac function in twin-twin transfusion syndrome.
        Ultrasound Obstet Gynecol. 2010; 35: 19-27
        • Tei C.
        • Ling L.H.
        • Hodge D.O.
        • et al.
        New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function--a study in normals and dilated cardiomyopathy.
        J Cardiol. 1999; 26: 357-366
        • Friedman D.
        • Buyon J.
        • Kim M.
        • Glickstein J.S.
        Fetal cardiac function assessed by Doppler myocardial performance index (Tei Index).
        Ultrasound Obstet Gynecol. 2003; 21: 33-36
        • Mackie F.L.
        • Hall M.J.
        • Morris R.K.
        • Kilby M.D.
        Early prognostic factors of outcomes in monochorionic twin pregnancy: systematic review and meta-analysis.
        Am J Obstet Gynecol. 2018; 219: 436-446
        • Van Mieghem T.
        • Doné E.
        • Gucciardo L.
        • et al.
        Amniotic fluid markers of fetal cardiac dysfunction in twin-to-twin transfusion syndrome.
        Am J Obstet Gynecol. 2010; 202: 48.e1-48.e7
        • Habli M.
        • Cnota J.
        • Michelfelder E.
        • et al.
        The relationship between amniotic fluid levels of brain-type natriuretic peptide and recipient cardiomyopathy in twin-twin transfusion syndrome.
        Am J Obstet Gynecol. 2010; 203: 404.e1-404.e7
        • Fasoulakis Z.
        • Theodora M.
        • Tsirkas I.
        • et al.
        The role of microRNAs identified in the amniotic fluid.
        Microrna. 2020; 9: 8-16
        • Zhao Z.
        • Moley K.H.
        • Gronowski A.M.
        Diagnostic potential for miRNAs as biomarkers for pregnancy-specific diseases.
        Clin Biochem. 2013; 46: 953-960
        • Topkara V.K.
        • Mann D.L.
        Role of microRNAs in cardiac remodeling and heart failure.
        Cardiovasc Drugs Ther. 2011; 25: 171-182
        • Du J.
        • Li M.
        • Huang Q.
        • et al.
        The critical role of microRNAs in stress response: therapeutic prospect and limitation.
        Pharmacol Res. 2019; 142: 294-302
        • Mendell J.T.
        • Olson E.N.
        MicroRNAs in stress signaling and human disease.
        Cell. 2012; 148: 1172-1187
        • Miyamoto S.D.
        • Karimpour-Fard A.
        • Peterson V.
        • et al.
        Circulating microRNA as a biomarker for recovery in pediatric dilated cardiomyopathy.
        J Heart Lung Transplant. 2015; 34: 724-733
        • Weber J.A.
        • Baxter D.H.
        • Zhang S.
        • et al.
        The microRNA spectrum in 12 body fluids.
        Clin Chem. 2010; 56: 1733-1741
        • Reddy S.
        • Zhao M.
        • Hu D.Q.
        • et al.
        Dynamic microRNA expression during the transition from right ventricular hypertrophy to failure.
        Physiol Genomics. 2012; 44: 562-575
        • Sucharov C.C.
        • Sucharov J.
        • Karimpour-Fard A.
        • Nunley K.
        • Stauffer B.L.
        • Miyamoto S.D.
        Micro-RNA expression in hypoplastic left heart syndrome.
        J Card Fail. 2015; 21: 83-88
        • Stauffer B.L.
        • Russell G.
        • Nunley K.
        • Miyamoto S.D.
        • Sucharov C.C.
        MiRNA expression in pediatric failing human heart.
        J Mol Cell Cardiol. 2013; 57: 43-46
        • Sun T.
        • Li W.
        • Li T.
        • Ling S.
        MicroRNA Profiling of amniotic fluid: evidence of synergy of microRNAs in fetal development.
        PLoS One. 2016; 11e0153950
        • Karaca E.
        • Aykut A.
        • Ertürk B.
        • et al.
        MicroRNA expression profile in the prenatal amniotic fluid samples of pregnant women with down syndrome.
        Balkan Med J. 2018; 35: 163-166
        • Xie J.
        • Zhou Y.
        • Gao W.
        • Li Z.
        • Xu Z.
        • Zhou L.
        The relationship between amniotic fluid miRNAs and congenital obstructive nephropathy.
        Am J Transl Res. 2017; 9: 1754-1763
        • Schuchardt E.L.
        • Crombleholme T.M.
        • Zuk J.
        • et al.
        The unique micro-RNA signature in amniotic fluid of recipients fetuses with twin-twin transfusion syndrome cardiomyopathy.
        Circulation. 2018; 138: A12747
        • Shi J.
        • Bei Y.
        • Kong X.
        • et al.
        miR-17-3p contributes to exercise-induced cardiac growth and protects against myocardial ischemia-reperfusion injury.
        Theranostics. 2017; 7: 664-676
        • Zhang Y.
        • Lu Y.
        • Ong’Achwa M.J.
        • et al.
        Resveratrol inhibits the TGF- β 1-induced proliferation of cardiac fibroblasts and collagen secretion by downregulating miR-17 in rat.
        BioMed Res Int. 2018; 2018: 8730593
        • Du W.W.
        • Li X.
        • Li T.
        • et al.
        The microRNA miR-17-3p inhibits mouse cardiac fibroblast senescence by targeting Par4.
        J Cell Sci. 2015; 128: 293-304
        • Zhou M.
        • Cai J.
        • Tang Y.
        • Zhao Q.
        MiR-17-92 cluster is a novel regulatory gene of cardiac ischemic/reperfusion injury.
        Med Hypotheses. 2013; 81: 108-110
        • Shi H.
        • Li J.
        • Song Q.
        • et al.
        Systematic identification and analysis of dysregulated miRNA and transcription factor feed-forward loops in hypertrophic cardiomyopathy.
        J Cell Mol Med. 2019; 23: 306-316
        • Gu H.
        • Liu Z.
        • Zhou L.
        Roles of MIR-17-92 cluster in cardiovascular development and common diseases.
        BioMed Res Int. 2017; 2017: 9102909
        • Danielson L.S.
        • Park D.S.
        • Rotllan N.
        • et al.
        Cardiovascular dysregulation of miR-17-92 causes a lethal hypertrophic cardiomyopathy and arrhythmogenesis.
        FASEB J. 2013; 27: 1460-1467
        • Chiang S.
        • Huang M.L.H.
        • Richardson D.R.
        Treatment of dilated cardiomyopathy in a mouse model of Friedreich’s ataxia using N-acetylcysteine and identification of alterations in microRNA expression that could be involved in its pathogenesis.
        Pharmacol Res. 2020; 159: 104994
        • Chen Z.
        • Zhang S.
        • Guo C.
        • Li J.
        • Sang W.
        Downregulation of miR-200c protects cardiomyocytes from hypoxia-induced apoptosis by targeting GATA-4.
        Int J Mol Med. 2017; 39: 1589-1596
        • Singh G.B.
        • Raut S.K.
        • Khanna S.
        • et al.
        MicroRNA-200c modulates DUSP-1 expression in diabetes-induced cardiac hypertrophy.
        Mol Cell Biochem. 2017; 424: 1-11
        • Hu S.
        • Cheng M.
        • Guo X.
        • et al.
        Down-regulation of miR-200c attenuates AngII-induced cardiac hypertrophy via targeting the MLCK-mediated pathway.
        J Cell Mol Med. 2019; 23: 2505-2516
        • Zhu P.
        • Yang M.
        • Ren H.
        • et al.
        Long noncoding RNA MALAT1 downregulates cardiac transient outward potassium current by regulating miR-200c/HMGB1 pathway.
        J Cell Biochem. 2018; 119: 10239-10249
        • Wang K.
        • Long B.
        • Zhou L.Y.
        • et al.
        CARL lncRNA inhibits anoxia-induced mitochondrial fission and apoptosis in cardiomyocytes by impairing miR-539-dependent PHB2 downregulation.
        Nat Commun. 2014; 5: 3596
        • Jeanson-Leh L.
        • Lameth J.
        • Krimi S.
        • et al.
        Serum profiling identifies novel muscle miRNA and cardiomyopathy-related miRNA biomarkers in golden retriever muscular dystrophy dogs and duchenne muscular dystrophy patients.
        Am J Pathol. 2014; 184: 2885-2898
        • Muthusamy S.
        • DeMartino A.M.
        • Watson L.J.
        • et al.
        MicroRNA-539 is up-regulated in failing heart, and suppresses O-GlcNAcase expression.
        J Biol Chem. 2014; 289: 29665-29676
        • Dassanayaka S.
        • Brittian K.R.
        • Long B.W.
        • et al.
        Cardiomyocyte Oga haploinsufficiency increases O-GlcNAcylation but hastens ventricular dysfunction following myocardial infarction.
        PLoS One. 2020; 15e0242250
        • Mackie F.L.
        • Baker B.C.
        • Beggs A.D.
        • Stodolna A.
        • Morris R.K.
        • Kilby M.D.
        MicroRNA changes in maternal serum from pregnancies complicated by twin-twin transfusion syndrome: a discovery study.
        Prenat Diagn. 2019; 39: 616-634
        • Hui L.
        • Wick H.C.
        • Moise K.J.
        • et al.
        Global gene expression analysis of amniotic fluid cell-free RNA from recipient twins with twin-twin transfusion syndrome.
        Prenat Diagn. 2013; 33: 873-883
        • Whitehead C.L.
        • Walker S.P.
        • Tong S.
        Measuring circulating placental RNAs to non-invasively assess the placental transcriptome and to predict pregnancy complications.
        Prenat Diagn. 2016; 36: 997-1008
        • Higashijima A.
        • Miura K.
        • Mishima H.
        • et al.
        Characterization of placenta-specific microRNAs in fetal growth restriction pregnancy.
        Prenat Diagn. 2013; 33: 214-222
        • Luo S.S.
        • Ishibashi O.
        • Ishikawa G.
        • et al.
        Human villous trophoblasts express and secrete placenta-specific microRNAs into maternal circulation via exosomes.
        Biol Reprod. 2009; 81: 717-729
        • Juracek J.
        • Piler P.
        • Janku P.
        • Radova L.
        • Slaby O.
        Identification of microRNA signatures in umbilical cord blood associated with maternal characteristics.
        PeerJ. 2019; 7: e6981